PURPOSE: The purpose of this study was to evaluate Interferon (IFN)-γ and Interleukin(IL)-17 profiles in patients with different clinical presentations of pulmonary tuberculosis (TB) and to compare them with those of tuberculin-negative and tuberculin-reactive healthy controls METHODS: Peripheral blood mononuclear cells (PBMCss), isolated from patients (n=52) and controls (n=30), were stimulated ex vivo with purified protein derivative (PPD) and IFN-γ and IL-17 levels in the supernatant were measured. RESULTS: At baseline, PBMCss from patients with TB released a significantly lower amount of IL-17 (p=0.043) than PBMCss from healthy controls, whereas IFN-γ levels were similar in the two groups. After PPD stimulation, a significant rise in IL-17 levels was found only among healthy controls (p=0.02). This rise in IL-17 levels was similar between tuberculin-reactive and tuberculin-negative subjects. After PPD stimulation, patients with infiltrative TB secreted higher levels of IL-17 and IFN-γ than those affected with chronic, miliary and cavitary TB (p < 0.01). IFN-γ production from patients with infiltrative TB was even higher than for healthy controls (p < 0.01). PBMCss from tuberculin-reactive patients released higher levels of IFN-γ than tuberculin-negative subjects after PPD stimulation (p < 0.01). CONCLUSION: Ex vivo PPD stimulation of PBMCs from patients with pulmonary TB does not significantly stimulate IL-17 release; however, higher IL-17 and IFN-γ levels are found in patients with infiltrative disease, in comparison with those affected with miliary, cavitary and chronic TB.
PURPOSE: The purpose of this study was to evaluate Interferon (IFN)-γ and Interleukin(IL)-17 profiles in patients with different clinical presentations of pulmonary tuberculosis (TB) and to compare them with those of tuberculin-negative and tuberculin-reactive healthy controls METHODS: Peripheral blood mononuclear cells (PBMCss), isolated from patients (n=52) and controls (n=30), were stimulated ex vivo with purified protein derivative (PPD) and IFN-γ and IL-17 levels in the supernatant were measured. RESULTS: At baseline, PBMCss from patients with TB released a significantly lower amount of IL-17 (p=0.043) than PBMCss from healthy controls, whereas IFN-γ levels were similar in the two groups. After PPD stimulation, a significant rise in IL-17 levels was found only among healthy controls (p=0.02). This rise in IL-17 levels was similar between tuberculin-reactive and tuberculin-negative subjects. After PPD stimulation, patients with infiltrative TB secreted higher levels of IL-17 and IFN-γ than those affected with chronic, miliary and cavitary TB (p < 0.01). IFN-γ production from patients with infiltrative TB was even higher than for healthy controls (p < 0.01). PBMCss from tuberculin-reactive patients released higher levels of IFN-γ than tuberculin-negative subjects after PPD stimulation (p < 0.01). CONCLUSION: Ex vivo PPD stimulation of PBMCs from patients with pulmonary TB does not significantly stimulate IL-17 release; however, higher IL-17 and IFN-γ levels are found in patients with infiltrative disease, in comparison with those affected with miliary, cavitary and chronic TB.
Authors: Neil M Ampel; Lance A Nesbit; Chinh T Nguyen; Suzette Chavez; Kenneth S Knox; Suzanne M Johnson; Demosthenes Pappagianis Journal: Clin Vaccine Immunol Date: 2015-06-03
Authors: Sigifredo Pedraza-Sánchez; Jose Luis Lezana-Fernández; Yolanda Gonzalez; Luis Martínez-Robles; María Laura Ventura-Ayala; Stanislaw Sadowinski-Pine; Margarita Nava-Frías; Sarbelio Moreno-Espinosa; Jean-Laurent Casanova; Anne Puel; Stephanie Boisson-Dupuis; Martha Torres Journal: Front Immunol Date: 2017-12-06 Impact factor: 7.561
Authors: Bas C Mourik; Erik Lubberts; Jurriaan E M de Steenwinkel; Tom H M Ottenhoff; Pieter J M Leenen Journal: Front Immunol Date: 2017-04-05 Impact factor: 7.561
Authors: André G Loxton; Julia K Knaul; Leander Grode; Andrea Gutschmidt; Christiane Meller; Bernd Eisele; Hilary Johnstone; Gian van der Spuy; Jeroen Maertzdorf; Stefan H E Kaufmann; Anneke C Hesseling; Gerhard Walzl; Mark F Cotton Journal: Clin Vaccine Immunol Date: 2017-02-06